Browsing by Subject "methadone"

Now showing 1 - 2 of 2
  • Thumbnail Image
    ItemOpen Access
    Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.
    (Substance abuse, 2021-01) Joudrey, Paul J; Bart, Gavin; Brooner, Robert K; Brown, Lawrence; Dickson-Gomez, Julie; Gordon, Adam; Kawasaki, Sarah S; Liebschutz, Jane M; Nunes, Edward; McCarty, Dennis; Schwartz, Robert P; Szapocnik, José; Trivedi, Madhukar; Tsui, Judith I; Williams, Arthur; Wu, Li-Tzy; Fiellin, David A
    In the US, methadone treatment can only be provided to patients with opioid use disorder (OUD) through federal and state-regulated opioid treatment programs (OTPs). There is a shortage of OTPs, and racial and geographic inequities exist in access to methadone treatment. The National Institute on Drug Abuse Center for Clinical Trials Network convened the Methadone Access Research Task Force to develop a research agenda to expand and create more equitable access to methadone treatment for OUD. This research agenda included mechanisms that are available within and outside the current regulations. The task force identified 6 areas where research is needed: (1) access to methadone in general medical and other outpatient settings; (2) the impact of methadone treatment setting on patient outcomes; (3) impact of treatment structure on outcomes in patients receiving methadone; (4) comparative effectiveness of different medications to treat OUD; (5) optimal educational and support structure for provision of methadone by medical providers; and (6) benefits and harms of expanded methadone access. In addition to outlining these research priorities, the task force identified important cross-cutting issues, including the impact of patient characteristics, treatment, and treatment system characteristics such as methadone formulation and dose, concurrent behavioral treatment, frequency of dispensing, urine or oral fluid testing, and methods of measuring clinical outcomes. Together, the research priorities and cross-cutting issues represent a compelling research agenda to expand access to methadone in the US.
  • Thumbnail Image
    ItemOpen Access
    Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.
    (Substance abuse, 2023-10) Jarrett, Jennie B; Bratberg, Jeffrey; Burns, Anne L; Cochran, Gerald; DiPaula, Bethany A; Legreid Dopp, Anna; Elmes, Abigail; Green, Traci C; Hill, Lucas G; Homsted, Felicity; Hsia, Stephanie L; Matthews, Michele L; Ghitza, Udi E; Wu, Li-Tzy; Bart, Gavin
    In the last decade, the U.S. opioid overdose crisis has magnified, particularly since the introduction of synthetic opioids, including fentanyl. Despite the benefits of medications for opioid use disorder (MOUD), only about a fifth of people with opioid use disorder (OUD) in the U.S. receive MOUD. The ubiquity of pharmacists, along with their extensive education and training, represents great potential for expansion of MOUD services, particularly in community pharmacies. The National Institute on Drug Abuse's National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) convened a working group to develop a research agenda to expand OUD treatment in the community pharmacy sector to support improved access to MOUD and patient outcomes. Identified settings for research include independent and chain pharmacies and co-located pharmacies within primary care settings. Specific topics for research included adaptation of pharmacy infrastructure for clinical service provision, strategies for interprofessional collaboration including health service models, drug policy and regulation, pharmacist education about OUD and OUD treatment, including didactic, experiential, and interprofessional curricula, and educational interventions to reduce stigma towards this patient population. Together, expanding these research areas can bring effective MOUD to where it is most needed.